 |
Quick Links |
| Information by Disease |
|
|
 |
| Cancer News |
|
|
 |
| Conference Coverage |
|
|
 |
| AZN | $47.72 | -0.86 (-1.77%)
| | NVS | $55.62 | -0.62 (-1.1%)
| | SNY | $35.51 | -0.33 (-0.92%)
| | GSK | $45.94 | -0.66 (-1.42%)
|
|
 |

Conference Coverage
2008 ASCO Genitourinary Cancers Symposium: Updates in the Management of Prostate and Kidney Cancers - CME C. Dean Buckner, MD ASCO 2007: Update on the Management of Genitourinary Malignancies Nancy A. Dawson, MD – Lombardi Comprehensive Cancer Center
|
| |
Current Topics
Proteomics: The Next Revolution in Prostate Cancer Diagnostics Rob Getzenberg, PhD, University of Pittsburgh Cancer Institute. January 2008.
|
|
|
Latest
Prostate Cancer
News
U.S. Preventive Service Task Force Does Not Recommend PSA Screening for Prostate Cancer (8/6/2008) Members of the U.S. Preventive Services Task Force have concluded that there is still insufficient evidence to recommend PSA screening in men 75 years of age or younger. The details of these recommendations were published in the August 5, 2008 issue of the Annals of Internal Medicine.
Abiraterone, an Inhibitor of Cytochrome P 17, Effective in Hormone Refractory Prostate Cancer (7/30/2008) Researchers from the United Kingdom have reported that the selective inhibitor of CYP17, abiraterone acetate, may be effective for the treatment of hormone refractory prostate cancer (HRPC). These results were published early online in the Journal of Clinical Oncology on July 21, 2008.
Low Socioeconomic Status Increases Cancer Mortality (7/24/2008) Researchers affiliated with the Findings from the National Program Registries Patterns of Care Study have reported that low socioeconomic status is associated with a high mortality due to later diagnoses and less aggressive treatments for cancer. The details of this study were reported in the August 1, 2008 issue of Cancer.
Radiofrequency Ablation Effective for Lung Tumors (7/22/2008) Researchers involved in a multicenter international trial have reported that the use of radiofrequency ablation for the treatment of lung cancer or pulmonary metastases provides an effective and safe therapeutic option for selected patients. These results were recently published in the July 7, 2008 issue of Lancet Oncology.
Denosumab Improves Bone Density in Prostate Cancer Patients (7/16/2008) Amgen has reported that denosumab improved bone density and reduced the risk of vertebral fracture in men with nonmetastatic prostate cancer receiving androgen-deprivation therapy (ADT).
More Prostate Cancer News »
|
|
Newsletters
Register in our member center today to receive a monthly newsletter with clinical
news, conference coverage, and current topic updates.
|
|
|
|
|
|